正在加载公司
Seaport Therapeutics, Inc.
SPTX · Nasdaq · ·
下次财报：2026年11月2日
US$18.77-4.1%9月29日 收盘
- 1M
- -20.5%
SPTX · Nasdaq · ·
下次财报：2026年11月2日
US$18.77-4.1%9月29日 收盘
Seaport Therapeutics, Inc. 预定于 2026年11月2日发布下一份财报。日期来自 Nasdaq 财报日历，公司有时会调整。
取自公司自己的 8-K 文件。
暂无 Seaport Therapeutics, Inc. 的业绩电话会文字记录。
“The second quarter of 2026 was marked by two major milestones for Seaport – positive results from our Phase 1 proof-of-concept trial of GlyphAgo and the successful completion of our IPO,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在收盘后或开盘前发布，因此这里的变动是随后的那个交易日。
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph TM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Seaport Therapeutics, Inc. 于 2026年8月3日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。